Literature DB >> 8198983

Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma.

N Abdelmoumene1, M Schlumberger, P Gardet, A Roche, J P Travagli, C Francese, C Parmentier.   

Abstract

Selective venous sampling catheterisation was performed in 19 patients with medullary thyroid carcinoma without known distant metastases for persistent hypercalcitoninaemia after surgery. Calcitonin (CT) gradients were found in the neck and/or the mediastinum in 18 patients and in five patients at distant sites also. After venous catheterisation, 13 patients were subjected to repeat surgery. Neck and/or mediastinal tumour foci were found in 12 patients at the sites of the CT gradients. Of these, nine patients had only cervicomediastinal CT gradients: after reoperation, the serum CT level normalised in one, significantly decreased in five, and did not change in three, and no neck relapse occurred after a mean follow-up of 5.3 years. Distant metastases emerged clinically in all five patients with distant gradients and in only one of the 14 patients with no distant gradient. In conclusion, selective venous catheterisation is the most sensitive tool for the localisation of residual disease and for the early detection of distant metastases. However, in patients with only local disease, biochemical cure is rarely obtained after reoperation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8198983      PMCID: PMC1969435          DOI: 10.1038/bjc.1994.224

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  8 in total

Review 1.  Changing concepts in the management of hereditary and sporadic medullary thyroid carcinoma.

Authors:  A Grauer; F Raue; R F Gagel
Journal:  Endocrinol Metab Clin North Am       Date:  1990-09       Impact factor: 4.741

2.  Value of venous catheterization and calcitonin studies in the treatment and management of clinically inapparent medullary thyroid carcinoma.

Authors:  M D Ben Mrad; P Gardet; A Roche; P Rougier; C Calmettes; P Motte; C Parmentier
Journal:  Cancer       Date:  1989-01-01       Impact factor: 6.860

3.  Early liver metastases in patients with medullary carcinoma of the thyroid gland.

Authors:  K M Gautvik; K Talle; B Hager; O G Jørgensen; M Aas
Journal:  Cancer       Date:  1989-01-01       Impact factor: 6.860

4.  Construction and clinical validation of a sensitive and specific assay for serum mature calcitonin using monoclonal anti-peptide antibodies.

Authors:  P Motté; P Vauzelle; P Gardet; P Ghillani; B Caillou; C Parmentier; C Bohuon; D Bellet
Journal:  Clin Chim Acta       Date:  1988-05-13       Impact factor: 3.786

5.  Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.

Authors:  J A van Heerden; C S Grant; H Gharib; I D Hay; D M Ilstrup
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

6.  [Tumours markers. Calcitonin and carcinoembryonic antigen in medullary carcinoma of the thyroid (author's transl)].

Authors:  C Calmettes; M S Moukhtar; G Milhaud
Journal:  Presse Med       Date:  1979-12-10       Impact factor: 1.228

7.  Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization.

Authors:  K Frank-Raue; F Raue; H J Buhr; G Baldauf; D Lorenz; R Ziegler
Journal:  Thyroid       Date:  1992       Impact factor: 6.568

8.  Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma.

Authors:  L E Tisell; G Hansson; S Jansson; H Salander
Journal:  Surgery       Date:  1986-01       Impact factor: 3.982

  8 in total
  4 in total

Review 1.  Surgical strategy for the treatment of medullary thyroid carcinoma.

Authors:  J B Fleming; J E Lee; M Bouvet; P N Schultz; S I Sherman; R V Sellin; K E Friend; M A Burgess; G J Cote; R F Gagel; D B Evans
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

2.  The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy.

Authors:  Zairong Gao; Hans J Biersack; Samer Ezziddin; Timur Logvinski; Rui An
Journal:  J Cancer Res Clin Oncol       Date:  2004-08-05       Impact factor: 4.553

3.  Identification of occult metastases of medullary thyroid carcinoma by pentagastrin-stimulated intravenous calcitonin sampling followed by targeted surgery.

Authors:  Matthias Schott; Holger S Willenberg; Cornelia Sagert; Thi-Bang-Tam Nguyen; Sven Schinner; Mathias Cohnen; Kenko Cupisti; Claus F Eisenberger; Wolfram T Knoefel; Werner A Scherbaum
Journal:  Clin Endocrinol (Oxf)       Date:  2007-03       Impact factor: 3.478

4.  Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging.

Authors:  G Pellegriti; S Leboulleux; E Baudin; N Bellon; C Scollo; J P Travagli; M Schlumberger
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.